Burjeel Holdings announced a partnership with Paige, a US-based leader in next-generation AI technology, to enhance access to advanced cancer diagnostics.
UAE healthcare major said it will deploy the US company’s AI-powered solutions across its healthcare network.
Burjeel, Paige join forces
The partnership also seeks to address the global shortage of pathologists and accelerate access to rapid, reliable cancer diagnostics, particularly in underserved communities and emerging markets.
Paige has developed a suite of AI applications that support diagnostic decision-making in cancer pathology.
“By incorporating next-gen AI into our pathology services, we aim to enhance the speed and accuracy of cancer diagnosis, enabling more effective treatment decisions,” said John Sunil, Group CEO of Burjeel Holdings.
“This partnership also reflects our mission to bring world-class, technology-enabled care to emerging markets,” he said.
Peter Hamilton, General Manager of Diagnostics, Paige, said Burjeel Holdings’ commitment to innovation and equitable care across the MENA region makes them a powerful ally in helping the company close diagnostic gaps and bring the benefits of our AI technology to more patients, faster.
“This partnership helps deliver on our mission to make next-generation cancer diagnostics accessible worldwide and aligns with our vision to standardise access to cutting-edge diagnostics on a global scale,” he said.
Paige has earned multiple regulatory achievements in AI for pathology, including FDA Breakthrough Device Designation for Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect.
Burjeel Holdings said it will deploy these AI applications along with Paige OmniScreen, which simultaneously screens over 1,600 molecular biomarkers to support comprehensive cancer diagnosis and more personalised treatment.
Follow us on
